secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIMEDX GROUP, INC. (MDXG)
CIK:        0001376339
Form:       8-K
Filed at:   2025-07-30T23:59:59+00:00
Accession:  0001376339-25-000087
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MiMedX Q2 net sales $99M record, up 13% YoY; raises 2025 growth to low double-digits
--------------------------------------------------------------------------------

- Net sales $99M (record), +13% YoY; GAAP net income $10M ($0.06 EPS); prior year included $9.3M settlement benefit.
- Adjusted EBITDA $24M (25% margin); cash $119M, up $15M from Dec 2024.
- Wound sales +12%, Surgical +15% YoY; driven by new products CELERA, EMERGE, HELIOGEN.
- Raises 2025 net sales growth outlook to low double-digits; reaffirms adjusted EBITDA margin above 20%.
- CEO supports CMS proposal to overhaul skin substitute reimbursement; engaging in comment period.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1376339/000137633925000087/0001376339-25-000087-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1376339/000137633925000087/mdxg-20250730.htm
  HTML page:      https://secwatch.observer/filing/0001376339-25-000087

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer